|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.030 USD | -4.73% |
|
-8.88% | -30.24% |
| 12-12 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 12-08 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
EPS & Dividend: Altimmune, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -0.9857 | -1.296 | -1.06 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 11.280 | 9.160 | 16.450 | 11.250 | 7.210 | 5.030 | 5.030 | 5.030 |
| Nbr of stocks (in thousands) | 36,968 | 39,644 | 49,146 | 53,729 | 71,125 | 104,342 | - | - |
| Announcement Date | 2/25/21 | 3/15/22 | 2/28/23 | 3/27/24 | 2/27/25 | - | - | - |
1USD in Million2USD
Estimates
Upcoming events: Altimmune, Inc.
| 2026-03-25 | Q4 2025 Earnings Release (Projected) |
| 2026-05-18 | Q1 2026 Earnings Release (Projected) |
| 2026-08-05 | Q2 2026 Earnings Release (Projected) |
| 2026-11-09 | Q3 2026 Earnings Release (Projected) |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | - | - | -5.36x | - | 127190.95x | |
| -.--% | -.--% | 46.99x | 7.65x | 11.45x | |
| -.--% | -.--% | -31.95x | 63.83x | 81.05x | |
| 1.77% | 1.67% | 16.07x | 3.8x | 5.63x | |
| -.--% | -.--% | -23.53x | 1.07x | 3.18x | |
| -.--% | -.--% | 17.14x | 3.22x | 4.23x | |
| -.--% | -.--% | 27.25x | 2.52x | 5.35x | |
| -.--% | -.--% | -479.05x | 13.13x | 27.63x | |
| -.--% | -.--% | -13.42x | - | 168.49x | |
| -.--% | -.--% | -56.86x | 21.09x | 12.83x | |
| Average | 0.2% | 0.19% | -50.27x | 14.54x | 12,751.08x | |
| Weighted average by Cap. | 0.29% | 0.28% | -23.68x | 17.43x | 332.95x |
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition